

9/10/04

# ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

<b>Title of Invention</b>	Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation
-------------------------------	---

Application Number : 10/709801

Confirmation Number: 2999


First Named Applicant: Caroline Despons

Attorney Docket Number: 1372.160.PRC

Art Unit:

Examiner:

Search string: ( 6025198 or 6703215 or 20040072298 ).pn



**US Patent Documents**

**Note: Applicant is not required to submit a paper copy of cited US Patent Documents**

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
83	1	6025198	2000-02-15	Bennett et al.	/	/	
	2	6703215	2004-03-09	Erneux et al.	/	/	

**US Published Applications**


**Note: Applicant is not required to submit a paper copy of cited US Published Applications**

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
82	1	20040072298	2004-04-15	Sauvageau et al.	/	/	

**Signature**

Examiner Name	Date
83	3-14-07



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/709,801
Filing Date	05/28/2004
First Named Inventor	Caroline Despons
Art Unit	1632 1635
Examiner Name	Unassigned
Attorney Docket Number	1372.160.PRC

Sheet	1	of	1
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JZ	1	HELGASON, CHERYL D. ET AL., Homeostasis and Regeneration of the Hematopoietic Stem Cell Pool are Altered in SHIP-Deficient Mice, Blood, 2003, 6541-3547, 102(10).	
L	2	MOODY, JENNIFER L. ET AL., Anemia, Thrombocytopenia, Leukocytosis, Extramedullary Hematopoiesis, and Impaired Progenitor Function in Pten+/-SHIP-/- Mice, Blood, 2004, 4503-4510	
L	3	TU, ZHENG ET AL., Embryonic and Hematopoietic Stem Cells Express a Novel SH2-Containing Inositol 5'-Phosphatase Isoform, Blood, 2001, 2028-2038, 98(7).	


Examiner Signature		Date Considered	3/14/07
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation/designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/709,801
				Filing Date	May 28, 2004
				First Named Inventor	Caroline Despons
				Art Unit	1622 1635
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	USF-212XZ1T

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
J3	U1	US-6,506,559 B1	01-14-2003	Fire et al.	All
J3	U2	US-5,804,412	09-08-1998	Gill et al.	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
J3	F1	WO	99/32619 A1	07-01-1999	Carnegie Inst. of Wash.	All
	F					
	F					
	F					
	F					
	F					
	F					

Examiner Signature	<i>J3</i>	Date Considered	3/14/07
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/709,801
Filing Date	May 28, 2004
First Named Inventor	Caroline Despons
Group Art Unit	1632 / 1635
Examiner Name	
Attorney Docket Number	USF-212XZ1T

Sheet	2	of	3
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
83	R1	AGRAWAL, N. <i>et al.</i> "RNA interference: biology, mechanism, and applications" <i>Microbiol. Mol. Biol. Rev.</i> , 2003, 67:657-685.	
	R2	BONETTA, L. "RNAi: Silencing never sounded better" <i>Nature Methods</i> , 2004, 1(1):79-86.	
	R3	CAPLEN, N.J. "RNAi as a gene therapy approach" <i>Expert Opin. Biol. Ther.</i> , 2003, 3:575-586.	
	R4	CAPLEN, N.J. <i>et al.</i> "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems" <i>PNAS</i> , 2001, 98(17):9742-9747.	
	R5	DAMEN, J.E. <i>et al.</i> "The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase" <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93:1689-1693.	
	R6	ELBASHIR, S. <i>et al.</i> "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells" <i>Nature</i> , 2001, 411:494-498.	
	R7	ELBASHIR, S. <i>et al.</i> "RNA interference is mediated by 21- and 22-nucleotide RNAs" <i>Genes &amp; Development</i> , 2001, 15:188-200.	
	R8	FIRE, A. <i>et al.</i> "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> " <i>Nature</i> , 1998, 391:806-811.	
	R9	HARBORTH, J. <i>et al.</i> "Identification of essential genes in cultured mammalian cells using small interfering RNAs" <i>J. Cell Sci.</i> , Dec. 2001, 114(Pt. 24):4557-4565.	
	R10	LIU, Q. <i>et al.</i> "Molecular cloning and chromosomal localization in human and mouse of the SH2-containing inositol phosphatase, INPP5D (SHIP)" <i>Genomics</i> , 1997, 39:109-112.	
	R11	MONTGOMERY, M.K. <i>et al.</i> "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Caenorhabditis elegans</i> " <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95:15502-15507.	
	R12	SVOBODA, P. <i>et al.</i> "Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference" <i>Development</i> , 2000, 127:4147-4156.	
	R13	TUSCHL, T. <i>et al.</i> "RNA interference and small interfering RNAs" <i>ChemBiochem</i> , 2001, 2(4):239-245.	

Examiner Signature		Date Considered	3/14/07
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/709,801
Filing Date	May 28, 2004
First Named Inventor	Caroline Despons
Group Art Unit	1632 1635
Examiner Name	
Attorney Docket Number	USF-212XZ1T

Sheet	3	of	3
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
J3	R14	TUSCHL, T. <i>et al.</i> "Targeted mRNA degradation by double-stranded RNA in vitro" <i>Genes &amp; Development</i> , 1999, 13:3191-3197.	
	R15	WARE, M.D. <i>et al.</i> "Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation" <i>Blood</i> , 1996, 88:2833-2840.	
	R16	ZAMORE, P. <i>et al.</i> "RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals" <i>Cell</i> , 2000, 101:25-33.	
J3	R17	Office Action mailed 12/29/2005 in U.S. Serial No. 09/955,174, filed September 19, 2001.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner Signature		Date Considered	3/14/07
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/709,801	
			Filing Date	May 28, 2004	
			First Named Inventor	Caroline Despons	
			Group Art Unit	1632 / 635	
			Examiner Name		
Sheet	1	of	1	Attorney Docket Number	USF-212XZ1T

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
83	R1	HANNON, G.J. and ROSSI, J.J. "Unlocking the potential of the human genome with RNA interference" <i>Nature</i> , 2004, 431:371-378.	
	R2	HEMANN, M.T. <i>et al.</i> "An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes <i>in vivo</i> " <i>Nature Genetics</i> , 2003, 33:396-400.	
	R3	OPALINSKA, J.B. and GEWIRTZ, A.M. "Nucleic-acid therapeutics: Basic principles and recent applications" <i>Nature Reviews</i> , 2002, 1:503-514.	
	R4	PERA, M.F. <i>et al.</i> "Human embryonic stem cells" <i>J. Cell Sci.</i> , 2000, 113:5-10.	
	R5	PUENTE, X.S. <i>et al.</i> "Human and mouse proteases: A comparative genomic approach" <i>Nature Reviews</i> , 2003, 4:544-558.	
	R6	RAUH, M.J. <i>et al.</i> "The role of SHIP1 in macrophage programming and activation" <i>Biochem. Soc. Trans.</i> , 2004, 32:785-788.	
	R7	REHLI, M. <i>et al.</i> "The membrane-bound ectopeptidase CPM as a marker of macrophage maturation <i>in vitro</i> and <i>in vivo</i> " <i>Adv. Exp. Med. Biol.</i> , 2000, 477:205-216.	
	R8	ROHRSCHEIDER, L.R. <i>et al.</i> "Structure, function, and biology of SHIP proteins" <i>Genes &amp; Develop.</i> , 2000, 14:505-520.	
	R9	VERFAILLIE, C.M. "Hematopoietic stem cells for transplantation" <i>Nature Immunology</i> , 2002, 3:314-317.	
	R10	ZANDSTRA, P.W. <i>et al.</i> "Leukemia inhibitory factor (LIF) concentration modulates embryonic stem cell self-renewal and differentiation independently of proliferation" <i>Biotechnol. Bioeng.</i> , 2000, 69:607-617.	
	R11	Examination Report dated November 11, 2006, issued in related European application number 01973144.7.	
	R12	GHANSAH, T. <i>et al.</i> "Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses" <i>J. Immunology</i> , 2004, 173:7324-7330.	
	R		

Examiner Signature		Date Considered	3/14/07
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.